IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
IGC Pharma, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.24−0.00 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $24.28M
- P/E (TTM)
- –
- Dividend yield
- –
IGC Pharma, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Legacy Infrastructure [Member] | – | – | – | $1.20M | – | – | $5.09M | $2.19M | – | – | – | – |
| Plant and Cannabinoid [Member] | – | – | – | – | – | – | $25.00K | – | – | – | – | – |
| Life Sciences [Member] | – | – | – | – | – | $411.00K | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plant and Cannabinoid [Member] | $1.27M | $1.35M | $798.00K | $359.00K | $723.00K | $411.00K | $25.00K | $0 | – | – | 100.0% | -5.5% |
| Life Sciences Segment [Member] | $1.27M | – | – | – | – | – | – | – | – | – | 100.0% | – |
| Tolling/White labeling service [Member] | $1.16M | $953.00K | $382.00K | $43.00K | $35.00K | – | – | – | – | – | 91.1% | +21.5% |
| White Labeling Services [Member] | $1.16M | – | – | – | – | – | – | – | – | – | 91.1% | – |
| Infrastructure Segment [Member] | $164.00K | – | – | – | – | – | – | – | – | – | 12.9% | – |
| Wellness and Lifestyle [Member] | $113.00K | $228.00K | $416.00K | $316.00K | $688.00K | – | – | – | – | – | 8.9% | -50.4% |
| Other Revenue [Member] | $0 | $164.00K | – | – | – | – | – | – | – | – | 0.0% | -100.0% |
| Trading [Member] | – | – | – | – | – | – | – | – | – | $6.25M | – | – |
| Rental/Lease [Member] | – | – | – | – | – | – | – | – | $367.28K | $114.75K | – | – |
| Trading, electronic component [Member] | – | – | – | – | – | – | – | – | $213.09K | – | – | – |
| Legacy Business [Member] | – | – | – | – | – | – | – | $2.19M | – | – | – | – |
| Alternative Therapies [Member] | – | – | – | – | – | – | – | $0 | – | – | – | – |
| Legacy Infrastructure [Member] | – | $164.00K | $113.00K | $38.00K | $175.00K | $3.66M | $5.09M | $2.19M | – | – | – | – |
| Construction [Member] | – | $146.00K | $76.00K | $15.00K | $174.00K | $101.00K | – | – | – | – | – | – |
| Rental Income [Member] | – | $18.00K | $37.00K | $23.00K | $1.00K | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.27M | $1.18M | $777.00K | $329.00K | – | – | – | $0 | – | – | 99.8% | +7.6% |
| Colombia | $2.00K | $2.00K | $21.00K | – | – | – | – | – | – | – | 0.2% | 0.0% |
| India | $0 | $164.00K | $113.00K | $68.00K | – | – | – | – | $124.87K | $114.75K | 0.0% | -100.0% |
| Hong Kong SAR China | – | – | – | – | – | – | – | $1.80M | $213.09K | $6.25M | – | – |
| Malaysia | – | – | – | – | – | – | – | – | $242.41K | – | – | – |
| Asia [Member] | – | – | – | – | – | – | – | $395.44K | – | – | – | – |
| North America [Member] | – | – | – | $329.00K | $723.00K | $411.00K | $25.00K | $0 | – | – | – | – |
From the segment and revenue-disaggregation notes of IGC Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.